Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sandoz And Polpharma Strike Global Deal For Natalizumab

Executive Summary

Polpharma and Sandoz have stuck a global licensing deal that gives the Novartis subsidiary rights to market the Polish firm’s biosimilar natalizumab rival to Biogen’s Tysabri.

You may also be interested in...



Polpharma Simplifies Structure By Absorbing Subsidiaries

Poland’s Polpharma SA has absorbed subsidiaries Polpharma BH and Medana Pharma as part of the group’s efforts to simplify management structures and processes and increase operational efficiency.

What’s Next? Five Things To Look Out For In March

In the month ahead, a key ANDA approval could come for Viatris, while additional competition to Gilead Sciences’ Truvada for PrEP is on the way in the US following Teva and Amneal’s launches.

Polpharma Biologics Rebrands As New Warsaw Site Is Validated

As it gears up to begin production at its new clinical and commercial manufacturing site in Warsaw, Polpharma Biologics has announced a new logo and corporate message to mark a year of “significant growth.”

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

GB149142

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel